TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Efficacy of the Use of Regional Anticoagulation With Citrate in Continuous Venovenous Hemofiltration, a Randomized Controlled Trial Comparing Anticoagulation With Citrate to the Low Molecular Weight Heparin Nadroparin
Brief Summary: Severely ill patients admitted to the intensive care unit may develop an acute failure of kidney function. To bridge the period to recovery, renal function is temporarily replaced by continuous venovenous hemofiltration (CVVH). To prevent clotting of the hemofiltration circuit, heparin is generally used, providing anticoagulation in the circuit and the patient. As a result, bleeding complications may occur, necessitating the transfusion of blood. Anticoagulation of the circuit can also be obtained with the use of tri-sodium citrate, which provides anticoagulation of the circuit without affecting coagulation in the patient and thus without increasing his/her risk of bleeding. The use of citrate may however cause metabolic complications.

Primary aim of the present study is to show in a larger group of intensive care patients whether the use of regional anticoagulation with citrate is safe compared to systemic anticoagulation with the low molecular weight heparin nadroparin.


Options:
A: Arm Label: Prismocitrate 18; Type: EXPERIMENTAL; Interventions: Drug: Prismocitrate 18 | Arm Label: No Regional Anticoagulation of CRRT Circuit; Type: ACTIVE_COMPARATOR; Interventions: Other: No Anticoagulation | Intervention Type: DRUG; Name: Prismocitrate 18; Assigned to Arm(s): Prismocitrate 18 | Intervention Type: OTHER; Name: No Anticoagulation; Assigned to Arm(s): No Regional Anticoagulation of CRRT Circuit
B: Arm Label: Higher intensity CRRT regimen; Type: EXPERIMENTAL; Interventions: Procedure: "augmented" CRRT regimen | Arm Label: Lower intensity CRRT regimen; Type: ACTIVE_COMPARATOR; Interventions: Procedure: "augmented" CRRT regimen | Intervention Type: PROCEDURE; Name: "augmented" CRRT regimen; Assigned to Arm(s): Higher intensity CRRT regimen, Lower intensity CRRT regimen
C: Arm Label: Dilute heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dilute unfractionated heparin | Arm Label: Standard concentrated heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard concentration unfractionated heparin | Intervention Type: DRUG; Name: Dilute unfractionated heparin; Assigned to Arm(s): Dilute heparin | Intervention Type: DRUG; Name: Standard concentration unfractionated heparin; Assigned to Arm(s): Standard concentrated heparin
D: Arm Label: citrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: trisodium citrate | Arm Label: nadroparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: nadroparin | Intervention Type: DRUG; Name: trisodium citrate; Assigned to Arm(s): citrate | Intervention Type: DRUG; Name: nadroparin; Assigned to Arm(s): nadroparin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rituximab in the Treatment of Patients With Bullous Pemphigoid
Brief Summary: This study will determine the safety of treatment of bullous pemphigoid in patients resistant to therapy with systemic corticosteroids, with rituximab plus systemic corticosteroids.


Options:
A: Arm Label: Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Rituximab | Arm Label: Corticotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: General Corticotherapy | Intervention Type: DRUG; Name: General Corticotherapy; Assigned to Arm(s): Corticotherapy | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Rituximab
B: Arm Label: Treatment Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Rituximab | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Treatment Rituximab
C: Arm Label: Part A; Type: PLACEBO_COMPARATOR; Interventions: Drug: BIV009, Other: Placebo | Arm Label: Part B; Type: PLACEBO_COMPARATOR; Interventions: Drug: BIV009, Other: Placebo | Arm Label: Part C; Type: EXPERIMENTAL; Interventions: Drug: BIV009 | Arm Label: Part E; Type: EXPERIMENTAL; Interventions: Drug: BIV009 | Intervention Type: DRUG; Name: BIV009; Assigned to Arm(s): Part A, Part B, Part C, Part E | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Part A, Part B
D: Intervention Type: DRUG; Name: Azathioprine or Mycophenolate mofetil; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With Insulin in Subjects With Type 2 Diabetes
Brief Summary: The purpose of this study is to determine the efficacy and safety of alogliptin, once daily (QD), taken in combination with insulin for the treatment of Type 2 Diabetes.


Options:
A: Arm Label: Pramlintide; Type: ACTIVE_COMPARATOR; Interventions: Drug: pramlintide acetate | Intervention Type: DRUG; Name: pramlintide acetate; Assigned to Arm(s): Pramlintide
B: Arm Label: Linagliptin; Type: EXPERIMENTAL; Interventions: Drug: Linagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Linagliptin; Assigned to Arm(s): Linagliptin
C: Arm Label: Insulin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Insulin | Arm Label: Alogliptin 12.5 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Alogliptin and insulin | Arm Label: Alogliptin 25 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Alogliptin and insulin | Intervention Type: DRUG; Name: Alogliptin and insulin; Assigned to Arm(s): Alogliptin 12.5 mg QD | Intervention Type: DRUG; Name: Alogliptin and insulin; Assigned to Arm(s): Alogliptin 25 mg QD | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Insulin
D: Arm Label: Saxagliptin, 5 mg + insulin; Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, 5 mg + insulin | Arm Label: Placebo + insulin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + insulin | Intervention Type: DRUG; Name: Saxagliptin, 5 mg + insulin; Assigned to Arm(s): Saxagliptin, 5 mg + insulin | Intervention Type: DRUG; Name: Placebo + insulin; Assigned to Arm(s): Placebo + insulin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Full Thickness Macular Hole and Internal Limiting Membrane Peeling Study: Randomised Comparison of Macular Hole Surgery With or Without Internal Limiting Membrane Peeling
Brief Summary: A macular hole is a fairly common problem in the retina and is an important cause of loss of central vision. The aim of this study is to determine whether, in patients with a stage 2 or 3 full thickness macular hole (FTMH), peeling a very fine, transparent tissue that covers the surface of the retina, called the internal limiting membrane (ILM) during surgery is superior to non-ILM peeling macular hole surgery. The main outcomes are improvement in vision, achievement of macular hole closure, need for re-operation, health related quality of life (HRQOL) and cost effectiveness.


Options:
A: Arm Label: Ocriplasmin 125µg; Type: EXPERIMENTAL; Interventions: Drug: Ocriplasmin 125µg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ocriplasmin 125µg; Assigned to Arm(s): Ocriplasmin 125µg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 125µg Ocriplasmin; Type: EXPERIMENTAL; Interventions: Drug: 125 µg Ocriplasmin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 125 µg Ocriplasmin; Assigned to Arm(s): 125µg Ocriplasmin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: macular hole operation no peeling; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Macular hole operation ICG peeling; Type: ACTIVE_COMPARATOR; Interventions: Procedure: macular hole operation | Arm Label: Macular hole operation TB peeling; Type: EXPERIMENTAL; Interventions: Procedure: macular hole operation | Intervention Type: PROCEDURE; Name: macular hole operation; Assigned to Arm(s): Macular hole operation ICG peeling, Macular hole operation TB peeling
D: Arm Label: ILM peeling; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Vitrectomy, post hyaloid detachment and gas injection with or without ILM peel. | Arm Label: No ILM peeling; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Vitrectomy, post hyaloid detachment and gas injection with or without ILM peel. | Intervention Type: PROCEDURE; Name: Vitrectomy, post hyaloid detachment and gas injection with or without ILM peel.; Assigned to Arm(s): ILM peeling, No ILM peeling

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-Center Trial on the Effect of Anesthetics on Morbidity and Mortality in Patients Undergoing Major Non-cardiac Surgery
Brief Summary: Volatile anesthetics may provide some protection from myocardial ischemia, an effect called anesthetic preconditioning. In patients undergoing coronary artery bypass surgery, this preconditioning effect resulted in better cardiac performance, faster recovery and lower morbidity and mortality.

The investigators will perform a prospective randomized multi-center study to compare volatile with total intravenous anesthesia in patients at a high cardiac risk who undergo major non-cardiac surgery.


Options:
A: Arm Label: Liberal (10 g/dL) Transfusion Strategy; Type: EXPERIMENTAL; Interventions: Biological: Liberal (10 g/dL) Transfusion Strategy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Restrictive (Symptomatic) Transfusion Strategy | Intervention Type: BIOLOGICAL; Name: Liberal (10 g/dL) Transfusion Strategy; Assigned to Arm(s): Liberal (10 g/dL) Transfusion Strategy | Intervention Type: BIOLOGICAL; Name: Restrictive (Symptomatic) Transfusion Strategy; Assigned to Arm(s): 2
B: Arm Label: Inhalational anesthetic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Inhalational anesthetic | Arm Label: Intravenous anesthetic, propofol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous anesthetic, propofol | Intervention Type: DRUG; Name: Inhalational anesthetic; Assigned to Arm(s): Inhalational anesthetic | Intervention Type: DRUG; Name: Intravenous anesthetic, propofol; Assigned to Arm(s): Intravenous anesthetic, propofol
C: Arm Label: multifaceted prevention program; Type: EXPERIMENTAL; Interventions: Behavioral: Multifaceted prevention program HELP(Hospital Elder Life Program) | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Multifaceted prevention program HELP(Hospital Elder Life Program); Assigned to Arm(s): multifaceted prevention program
D: Arm Label: Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dexamethasone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone, Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-Center Trial on the Effect of Anesthetics on Morbidity and Mortality in Patients Undergoing Major Non-cardiac Surgery
Brief Summary: Volatile anesthetics may provide some protection from myocardial ischemia, an effect called anesthetic preconditioning. In patients undergoing coronary artery bypass surgery, this preconditioning effect resulted in better cardiac performance, faster recovery and lower morbidity and mortality.

The investigators will perform a prospective randomized multi-center study to compare volatile with total intravenous anesthesia in patients at a high cardiac risk who undergo major non-cardiac surgery.


Options:
A: N/A
B: N/A
C: Arm Label: Inhalational anesthetic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Inhalational anesthetic | Arm Label: Intravenous anesthetic, propofol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous anesthetic, propofol | Intervention Type: DRUG; Name: Inhalational anesthetic; Assigned to Arm(s): Inhalational anesthetic | Intervention Type: DRUG; Name: Intravenous anesthetic, propofol; Assigned to Arm(s): Intravenous anesthetic, propofol
D: Intervention Type: PROCEDURE; Name: Acute abdominal surgery; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Can Group Visits Improve Outcomes of Veterans With Diabetes
Brief Summary: Background: Diabetes is a common, morbid and expensive disease among veterans. Achieving adequate glycemic control and blood pressure control can reduce the devastating complications of diabetes. Because the majority of patients do not achieve adequate control of blood sugar and blood pressure, innovative strategies to improve control are needed. One strategy with great potential for veterans receiving VA care is the group clinic. Group clinics have been developed over the last 5-10 years, and have been shown to improve clinical outcomes and reduce outpatient utilization in geriatric settings. Group medical clinics involve a cohort of 8-20 patients who have 1-2 hour group visits. These clinics are distinguished from traditional group education visits for diabetes by the fact that these visits involve one physician and one or more additional health care professionals, usually a nurse practitioner and/or a pharmacist, and are designed to make management changes for a number of people with the same disease in a short period of time. The effect of group medical clinics on blood sugar, blood pressure, and the cost of diabetes care, is unknown. Objectives: Our primary objectives in this project are to determine the effectiveness and cost-effectiveness of a group visit intervention in improving rates of control of diabetes and high blood pressure in patients with both illnesses.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Mobile Health Care Environment (MHCE) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Mobile Health Care Environment (MHCE); Assigned to Arm(s): Intervention
B: Arm Label: Medical group visits; Type: EXPERIMENTAL; Interventions: Other: Diabetes Group Management Visits | Arm Label: Treatment as Usual control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Diabetes Group Management Visits; Assigned to Arm(s): Medical group visits
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Toolkit | Arm Label: Control; Type: OTHER; Interventions: Other: Control | Intervention Type: OTHER; Name: Toolkit; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
D: Arm Label: Training course for practice nurses in autonomy support; Type: EXPERIMENTAL; Interventions: Behavioral: Training course for practice nurses in autonomy support | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Training course for practice nurses in autonomy support; Assigned to Arm(s): Training course for practice nurses in autonomy support

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Growing Future Physician Leaders: A Randomized, Controlled Trial of an Educational Intervention in Postgraduate Trainees
Brief Summary: Study objective: The objective of this trial was to determine the effectiveness of a Leadership Development Program (LDP) aimed at 1) establishing basic management knowledge and 2) promoting reflection of leadership skills.

Study design: Randomized, controlled, single-blind trial. Study participants: Senior postgraduate medical and surgical trainees at an urban university health care centre.

Methods: Eligible participants were randomized to either the LDP(intervention group) or to regular postgraduate training (control group). For ethical reasons, all participants assigned to the control group were offered the LDP at the end of the trial. The 1º outcome measure used was a knowledge-based written exam. The sample size was estimated on finding a 20% difference in mean test scores between groups. Participants' reflective capacity and higher order leadership role skills were tested through a personal learning project (PLP, 2º outcome measure).


Options:
A: Intervention Type: BEHAVIORAL; Name: Leadership development program educational intervention; Assigned to Arm(s): N/A
B: Arm Label: Retreat; Type: EXPERIMENTAL; Interventions: Other: Retreat | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Retreat; Assigned to Arm(s): Retreat
C: Arm Label: Educational Intervention; Type: EXPERIMENTAL; Interventions: Other: Assessing the Effect Of Educational Intervention Based On Supportive Leadership Behavior on Iranian head nurses leadership performance | Arm Label: CONTROL; Type: PLACEBO_COMPARATOR; Interventions: Other: Assessing the Effect Of Educational Intervention Based On Supportive Leadership Behavior on Iranian head nurses leadership performance | Intervention Type: OTHER; Name: Assessing the Effect Of Educational Intervention Based On Supportive Leadership Behavior on Iranian head nurses leadership performance; Assigned to Arm(s): CONTROL, Educational Intervention
D: Arm Label: State of the Art strategy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: state-of-the art strategy and extented strategy | Arm Label: extended strategy; Type: EXPERIMENTAL; Interventions: Behavioral: state-of-the art strategy and extented strategy | Intervention Type: BEHAVIORAL; Name: state-of-the art strategy and extented strategy; Assigned to Arm(s): State of the Art strategy, extended strategy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adoptive Cell Therapy Following Non-myeloablate Chemotherapy in Metastatic Melanoma Patients
Brief Summary: Metastatic melanoma is an aggressive and highly malignant cancer. The five-year survival rate of patients with metastatic disease is less than 5% with a median survival of only 6-10 months. Drugs like Dacarbazin (DTIC) as a single agent or in combination with other chemotherapy agents, have a response rate of 15-30%, but the duration of response is usually short, with no impact on survival. Interleukin-2 (IL-2) based immunotherapy has shown more promising results. This form of therapy has a similar response rate with some patients achieving a durable complete response. Recently the National Institute of Health (NIH) reported that by using lympho-depleting chemotherapy, followed by an adoptive transfer of large numbers of anti-tumor specific tumor-infiltrating lymphocytes (TIL), an objective regression was achieved in 51% of patients with metastatic melanoma.

Objectives: To introduce the TIL technology to advanced metastatic melanoma patients in Israel.


Options:
A: Arm Label: CD30 positive NHL subtypes; Type: EXPERIMENTAL; Interventions: Drug: CD30.CAR-T | Intervention Type: DRUG; Name: CD30.CAR-T; Assigned to Arm(s): CD30 positive NHL subtypes
B: Arm Label: Axicabtagene Ciloleucel Treatment; Type: EXPERIMENTAL; Interventions: Biological: Axicabtagene Ciloleucel, Drug: Cyclophosphamide, Drug: Fludarabine | Arm Label: Standard of Care Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders. | Intervention Type: BIOLOGICAL; Name: Axicabtagene Ciloleucel; Assigned to Arm(s): Axicabtagene Ciloleucel Treatment | Intervention Type: DRUG; Name: Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.; Assigned to Arm(s): Standard of Care Therapy | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Axicabtagene Ciloleucel Treatment | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): Axicabtagene Ciloleucel Treatment
C: Arm Label: single arm; Type: EXPERIMENTAL; Interventions: Biological: CD19-targeted CAR-T cells | Intervention Type: BIOLOGICAL; Name: CD19-targeted CAR-T cells; Assigned to Arm(s): single arm
D: Intervention Type: PROCEDURE; Name: Procedure - Adoptive cell transfer; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Randomized Controlled Trial of Azithromycin or Artesunate Added to Sulphadoxine Pyrimethamine as Therapy for Malaria in Pregnancy
Brief Summary: The purpose of this study is to compare the efficacy and safety of three treatment regimens for the prevention of malaria during pregnancy.


Options:
A: Intervention Type: DRUG; Name: Sulfadoxine-Pyrimethamine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Artesunate; Assigned to Arm(s): N/A
B: Arm Label: 1AZ+AQ; Type: EXPERIMENTAL; Interventions: Drug: azithromycin + artesunate | Arm Label: 2AL; Type: ACTIVE_COMPARATOR; Interventions: Drug: artemether-lumefantrine | Intervention Type: DRUG; Name: azithromycin + artesunate; Assigned to Arm(s): 1AZ+AQ | Intervention Type: DRUG; Name: artemether-lumefantrine; Assigned to Arm(s): 2AL
C: Arm Label: Azithromycin + Artesunate; Type: EXPERIMENTAL; Interventions: Drug: azithromycin plus artesunate | Arm Label: Artesunate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artesunate | Intervention Type: DRUG; Name: azithromycin plus artesunate; Assigned to Arm(s): Azithromycin + Artesunate | Intervention Type: DRUG; Name: Artesunate; Assigned to Arm(s): Artesunate
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin plus Chloroquine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Artemether-lumefantrine | Intervention Type: DRUG; Name: Azithromycin plus Chloroquine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Artemether-lumefantrine; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Terlipressin as Treatment of Patients With Cirrhosis and Hepatorenal Syndrome. Effect on Survival and Renal Function. Multicenter, Randomized and Prospective Study
Brief Summary: Hepatorenal syndrome is a common complication of cirrhotic patients. The prognosis of patients with HRS is very poor. It have been demonstrated that vasoconstrictors agents (Terlipressin) plus albumin are effective in the reversal of the treatment. However, previous studies are pilot studies and they are not able to give information about an improvement in survival. This comparative randomized study was delineated to test the efficacy of terlipressin on survival.


Options:
A: Arm Label: Terlipressin; Type: EXPERIMENTAL; Interventions: Drug: terlipressin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: terlipressin; Assigned to Arm(s): Terlipressin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Terlipressin; Type: EXPERIMENTAL; Interventions: Drug: Terlipressin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): Terlipressin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Terlipressin | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Noradrenalin | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Noradrenalin; Assigned to Arm(s): 1
D: Intervention Type: DRUG; Name: terlipressin; Assigned to Arm(s): N/A

Answer: D